Presentation is loading. Please wait.

Presentation is loading. Please wait.

(A) Annual proportion of new users and (B) proportion of overall use of each product over the study period. (A) Annual proportion of new users and (B)

Published byQuentin Samson Modified over 5 years ago

Similar presentations

Presentation on theme: "(A) Annual proportion of new users and (B) proportion of overall use of each product over the study period. (A) Annual proportion of new users and (B)"— Presentation transcript:

1 (A) Annual proportion of new users and (B) proportion of overall use of each product over the study period. (A) Annual proportion of new users and (B) proportion of overall use of each product over the study period. CPA/EE, cyproterone acetate/ethinylestradiol; DRSP/EE, drospirenone/ethinylestradiol; LNG/EE, levonorgestrel/ethinylestradiol. Lucía Cea-Soriano et al. J Fam Plann Reprod Health Care 2016;42: Copyright © by the BMJ Publishing Group Ltd & the Faculty of Sexual & Reproductive Healthcare of the Royal College of Obstetricians & Gynaecologists. All rights reserved.

Download ppt "(A) Annual proportion of new users and (B) proportion of overall use of each product over the study period. (A) Annual proportion of new users and (B)"

Similar presentations

 Categorisation of direct and indirect admissions to the intensive care unit (ICU) from emergency departments (EDs), using source of admission.  Categorisation.

 Categorisation of direct and indirect admissions to the intensive care unit (ICU) from emergency departments (EDs), using source of admission.  Categorisation.
Number of days from insertion of intrauterine device or intrauterine system to first major event in patients receiving frequent or infrequent systematic.

Number of days from insertion of intrauterine device or intrauterine system to first major event in patients receiving frequent or infrequent systematic.
 Correlation between plasma total antioxidant capacity of plasma (TAC) and protein SH groups (SH) (A), total hydroperoxide concentration (TH) and TAC (B),

 Correlation between plasma total antioxidant capacity of plasma (TAC) and protein SH groups (SH) (A), total hydroperoxide concentration (TH) and TAC (B),
EEG maximal power frequency and relative power frequency distribution from 12 surface electrodes (horizontal axis) in children with (open circles) and.

EEG maximal power frequency and relative power frequency distribution from 12 surface electrodes (horizontal axis) in children with (open circles) and.
Box plot of subarachnoid space measurements at each gestational week of age. Box plot of subarachnoid space measurements at each gestational week of age.

Box plot of subarachnoid space measurements at each gestational week of age. Box plot of subarachnoid space measurements at each gestational week of age.
 Diagram of apparatus used to assess accuracy of measurements made with flow sensor 1 (FS1) using flow sensor 2 (FS2).  Diagram of apparatus used to assess.

 Diagram of apparatus used to assess accuracy of measurements made with flow sensor 1 (FS1) using flow sensor 2 (FS2).  Diagram of apparatus used to assess.
Normal ranges by corrected gestational age at scan for bFFE assessment of left ventricular output (A), end-diastolic volume (B), end-systolic volume (C)

Normal ranges by corrected gestational age at scan for bFFE assessment of left ventricular output (A), end-diastolic volume (B), end-systolic volume (C)
Box plot of head circumference measurements at each gestational week of age. Box plot of head circumference measurements at each gestational week of age.

Box plot of head circumference measurements at each gestational week of age. Box plot of head circumference measurements at each gestational week of age.
Pulse field gel electrophoresis: Lane 1 Lamda marker; lanes 2 to 5 K pneumoniae isolates from cases 3 to 6; lane 6 isolate from case 7; lane 7 ESBL negative.

Pulse field gel electrophoresis: Lane 1 Lamda marker; lanes 2 to 5 K pneumoniae isolates from cases 3 to 6; lane 6 isolate from case 7; lane 7 ESBL negative.
Flow chart of patients undergoing intra-caesarean insertion of postplacental intrauterine contraceptive device (PPIUD). Flow chart of patients undergoing.

Flow chart of patients undergoing intra-caesarean insertion of postplacental intrauterine contraceptive device (PPIUD). Flow chart of patients undergoing.
Plot of average differences in arterial blood pressure using the two methods in mm Hg against both methods for systolic blood pressure (A) and diastolic.

Plot of average differences in arterial blood pressure using the two methods in mm Hg against both methods for systolic blood pressure (A) and diastolic.
 Schematic representation of the two types of gastric volvulus: organoaxial volvulus occurs around the line A–A and mesenteroaxial volvulus occurs around.

 Schematic representation of the two types of gastric volvulus: organoaxial volvulus occurs around the line A–A and mesenteroaxial volvulus occurs around.
Examples of Mirena® Haptic ‘end effectors’

Examples of Mirena® Haptic ‘end effectors’
Box plot representation of serum cytokines levels (pg/ml) in group A (nasal continuous positive airway pressure (NCPAP)) and group B (bi-level NCPAP) at.

Box plot representation of serum cytokines levels (pg/ml) in group A (nasal continuous positive airway pressure (NCPAP)) and group B (bi-level NCPAP) at.
Masashi Maeda et al. Heart Asia 2013;5:7-14

Masashi Maeda et al. Heart Asia 2013;5:7-14
Frequency histograms for proportion of time spent at each saturation value while receiving supplemental oxygen in infants monitored using un-modified Masimo.

Frequency histograms for proportion of time spent at each saturation value while receiving supplemental oxygen in infants monitored using un-modified Masimo.
Proportion of overall use stratified by age over the study period for (A) cyproterone acetate/ethinylestradiol, (B) levonorgestrel/ethinylestradiol and.

Proportion of overall use stratified by age over the study period for (A) cyproterone acetate/ethinylestradiol, (B) levonorgestrel/ethinylestradiol and.
Subgroup analysis of the 17 trials comparing haloperidol and placebo in schizophrenia (outcome: response rate). Subgroup analysis of the 17 trials comparing.

Subgroup analysis of the 17 trials comparing haloperidol and placebo in schizophrenia (outcome: response rate). Subgroup analysis of the 17 trials comparing.
Funnel plot of the 17 trials comparing haloperidol and placebo in schizophrenia (outcome: response rate). Funnel plot of the 17 trials comparing haloperidol.

Funnel plot of the 17 trials comparing haloperidol and placebo in schizophrenia (outcome: response rate). Funnel plot of the 17 trials comparing haloperidol.
Drawing illustrating the interaction between weight and insulin resistance, leading to augmentation of luteinising hormone (LH)-stimulated androgen (A)

Drawing illustrating the interaction between weight and insulin resistance, leading to augmentation of luteinising hormone (LH)-stimulated androgen (A)

Similar presentations

Ads by Google